Oruka Therapeutics (NASDAQ:ORKA) Shares Down 7.4% - Here's Why

Key Points

• Oruka Therapeutics shares fell 7.4% to about $87.57 in midday trading, with volume down 60% from the average session. The company recently missed quarterly EPS expectations, reporting a loss of $0.55 per share versus the $0.51 consensus estimate.
• Despite the decline, analysts remain broadly positive: 10 rate the stock a Buy and one a Sell, producing a “Moderate Buy” consensus and an average price target of $133, well above the recent trading price.
• Company insiders sold 122,950 shares worth approximately $11.5 million in the last quarter, including sales by the CEO and a senior vice president. Institutional investors own 56.44% of the stock, while Oruka continues developing long-acting antibody therapies for immune-mediated diseases.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) shares traded down 7.4% during mid-day trading on Wednesday . The company traded as low as $88.38 and last traded at $87.5710. 436,560 shares traded hands during trading, a decline of 60% from the average session volume of 1,093,720 shares. The stock had previously closed at $94.55.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. UBS Group increased their target price on Oruka Therapeutics from $100.00 to $130.00 and gave the company a "buy" rating in a research note on Wednesday, July 1st. Wall Street Zen lowered Oruka Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, August 16th. Piper Sandler restated an "overweight" rating and issued a $180.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. Weiss Ratings raised shares of Oruka Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, July 15th. Finally, BTIG Research reissued a "buy" rating and set a $151.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $133.00.

Oruka Therapeutics Stock Down 6.4%

The stock has a market cap of $5.86 billion, a price-to-earnings ratio of -43.60 and a beta of -0.34. The company's 50-day simple moving average is $96.72 and its 200-day simple moving average is $74.92.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). As a group, analysts expect that Oruka Therapeutics, Inc. will post -2.42 EPS for the current fiscal year.

Insider Activity at Oruka Therapeutics

In other Oruka Therapeutics news, CEO Lawrence Klein sold 75,000 shares of the company's stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $91.83, for a total transaction of $6,887,250.00. Following the completion of the sale, the chief executive officer directly owned 925,580 shares of the company's stock, valued at approximately $84,996,011.40. This represents a 7.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,000 shares of the firm's stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the completion of the transaction, the senior vice president owned 15,312 shares of the company's stock, valued at approximately $1,633,177.92. The trade was a 39.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 122,950 shares of company stock worth $11,528,806 in the last quarter. 23.49% of the stock is owned by company insiders.

Institutional Trading of Oruka Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Sei Investments Co. grew its stake in Oruka Therapeutics by 136.0% during the 1st quarter. Sei Investments Co. now owns 22,840 shares of the company's stock valued at $1,120,000 after acquiring an additional 13,164 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in Oruka Therapeutics during the first quarter valued at approximately $5,543,000. Handelsbanken Fonder AB purchased a new position in Oruka Therapeutics during the second quarter valued at approximately $15,313,000. The Manufacturers Life Insurance Company increased its stake in Oruka Therapeutics by 18.3% in the 1st quarter. The Manufacturers Life Insurance Company now owns 72,563 shares of the company's stock valued at $3,559,000 after buying an additional 11,205 shares during the period. Finally, Braidwell LP acquired a new position in Oruka Therapeutics in the 2nd quarter valued at approximately $26,473,000. Institutional investors and hedge funds own 56.44% of the company's stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc NASDAQ: ORKA is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company's research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka's initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.